- Home
- GAME vs SLGL Comparison
GAME vs SLGL Comparison
Compare GAME & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- SLGL
- Stock Information
- Founded
- GAME 2011
- SLGL 1997
- Country
- GAME United States
- SLGL Israel
- Employees
- GAME N/A
- SLGL N/A
- Industry
- GAME
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- SLGL Health Care
- Exchange
- GAME Nasdaq
- SLGL Nasdaq
- Market Cap
- GAME 70.2M
- SLGL 69.1M
- IPO Year
- GAME 2009
- SLGL 2018
- Fundamental
- Price
- GAME $0.74
- SLGL $24.35
- Analyst Decision
- GAME Strong Buy
- SLGL
- Analyst Count
- GAME 2
- SLGL 0
- Target Price
- GAME $3.00
- SLGL N/A
- AVG Volume (30 Days)
- GAME 2.6M
- SLGL 32.4K
- Earning Date
- GAME 11-13-2025
- SLGL 11-14-2025
- Dividend Yield
- GAME N/A
- SLGL N/A
- EPS Growth
- GAME N/A
- SLGL N/A
- EPS
- GAME N/A
- SLGL N/A
- Revenue
- GAME $93,375,339.00
- SLGL $23,931,000.00
- Revenue This Year
- GAME $2.32
- SLGL N/A
- Revenue Next Year
- GAME $26.42
- SLGL $31.17
- P/E Ratio
- GAME N/A
- SLGL N/A
- Revenue Growth
- GAME 54.19
- SLGL 264.86
- 52 Week Low
- GAME $0.50
- SLGL $4.01
- 52 Week High
- GAME $2.87
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- GAME 43.40
- SLGL 59.60
- Support Level
- GAME $0.70
- SLGL $23.13
- Resistance Level
- GAME $0.76
- SLGL $24.85
- Average True Range (ATR)
- GAME 0.05
- SLGL 2.20
- MACD
- GAME 0.01
- SLGL -0.53
- Stochastic Oscillator
- GAME 49.52
- SLGL 37.22
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.